{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T14:54:53Z","timestamp":1766156093371,"version":"3.48.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,19]]},"DOI":"10.7759\/cureus.99626","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T14:52:36Z","timestamp":1766155956000},"source":"Crossref","is-referenced-by-count":0,"title":["Low-Dose Vericiguat in Heart Failure With Reduced Ejection Fraction: A Case Report"],"prefix":"10.7759","author":[{"given":"Chinedu","family":"Orji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.113.300268","article-title":"Epidemiology of heart failure","volume":"113","author":"Roger VL","year":"2013","unstructured":"Roger VL. Epidemiology of heart failure. Circ Res. 2013, 113:646-59. 10.1161\/CIRCRESAHA.113.300268","journal-title":"Circ Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.15193","article-title":"Guideline-directed medical therapy rates in heart failure patients with reduced ejection fraction in a diverse cohort","volume":"12","author":"Berry NC","year":"2025","unstructured":"Berry NC, Sheu YS, Chesbrough K, Bishop RC, Vupputuri S. Guideline-directed medical therapy rates in heart failure patients with reduced ejection fraction in a diverse cohort. ESC Heart Fail. 2025, 12:1861-71. 10.1002\/ehf2.15193","journal-title":"ESC Heart Fail"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.112894","article-title":"Development of vericiguat: the first soluble guanylate cyclase (sGC) stimulator launched for heart failure with reduced ejection fraction (HFrEF)","volume":"149","author":"Xia J","year":"2022","unstructured":"Xia J, Hui N, Tian L, et al.. Development of vericiguat: the first soluble guanylate cyclase (sGC) stimulator launched for heart failure with reduced ejection fraction (HFrEF). Biomed Pharmacother. 2022, 149:112894. 10.1016\/j.biopha.2022.112894","journal-title":"Biomed Pharmacother"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411826","article-title":"A systematic review of the effect of vericiguat on patients with heart failure","volume":"24","author":"Sahana U","year":"2023","unstructured":"Sahana U, Wehland M, Simonsen U, Schulz H, Grimm D. A systematic review of the effect of vericiguat on patients with heart failure. Int J Mol Sci. 2023, 24:11826. 10.3390\/ijms241411826","journal-title":"Int J Mol Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong PW","year":"2020","unstructured":"Armstrong PW, Pieske B, Anstrom KJ, et al.. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020, 382:1883-93. 10.1056\/NEJMoa1915928","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14767","article-title":"Eligibility for vericiguat in a real-world, contemporary heart failure population","volume":"11","author":"Vergaro G","year":"2024","unstructured":"Vergaro G, Aimo A, Gentile F, et al.. Eligibility for vericiguat in a real-world, contemporary heart failure population. ESC Heart Fail. 2024, 11:3523-9. 10.1002\/ehf2.14767","journal-title":"ESC Heart Fail"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1504427","article-title":"Clinical profile of an unselected population with heart failure treated with vericiguat in real life: differences with the VICTORIA trial","volume":"11","author":"Esteban-Fern\u00e1ndez A","year":"2024","unstructured":"Esteban-Fern\u00e1ndez A, Recio-Mayoral A, L\u00f3pez-Vilella R, et al.. Clinical profile of an unselected population with heart failure treated with vericiguat in real life: differences with the VICTORIA trial. Front Cardiovasc Med. 2024, 11:1504427. 10.3389\/fcvm.2024.1504427","journal-title":"Front Cardiovasc Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-024-03654-0","article-title":"Real-world characteristics and use patterns of patients treated with vericiguat: a nationwide longitudinal cohort study in Germany","volume":"80","author":"Kerwagen F","year":"2024","unstructured":"Kerwagen F, Ohlmeier C, Evers T, et al.. Real-world characteristics and use patterns of patients treated with vericiguat: a nationwide longitudinal cohort study in Germany. Eur J Clin Pharmacol. 2024, 80:931-40. 10.1007\/s00228-024-03654-0","journal-title":"Eur J Clin Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S357422","article-title":"Vericiguat in heart failure with a reduced ejection fraction: patient selection and special considerations","volume":"18","author":"Kassis-George H","year":"2022","unstructured":"Kassis-George H, Verlinden NJ, Fu S, Kanwar M. Vericiguat in heart failure with a reduced ejection fraction: patient selection and special considerations. Ther Clin Risk Manag. 2022, 18:315-22. 10.2147\/TCRM.S357422","journal-title":"Ther Clin Risk Manag"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"145","author":"Heidenreich PA","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al.. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2022, 145:e895-e1032. 10.1161\/CIR.0000000000001063","journal-title":"Circulation"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1253\/circrep.CR-24-0076","article-title":"Effect of vericiguat on left ventricular reverse remodeling in patients who have heart failure with reduced ejection fraction - special focus on patients without quadruple medical therapy","volume":"6","author":"Fujii C","year":"2024","unstructured":"Fujii C, Hiraishi M, Yamashita K, et al.. Effect of vericiguat on left ventricular reverse remodeling in patients who have heart failure with reduced ejection fraction - special focus on patients without quadruple medical therapy. Circ Rep. 2024, 6:448-55. 10.1253\/circrep.CR-24-0076","journal-title":"Circ Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/440533-low-dose-vericiguat-in-heart-failure-with-reduced-ejection-fraction-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T14:52:37Z","timestamp":1766155957000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/440533-low-dose-vericiguat-in-heart-failure-with-reduced-ejection-fraction-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.99626","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,19]]}}}